Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J.
Lancet Neurol. 2023 Mar;22(3):268-282. doi: 10.1016/S1474-4422(22)00431-8. Epub 2023 Jan 24.
Double-negative neuromyelitis optica spectrum disorder.
Wu Y, Geraldes R, Juryńczyk M, Palace J.
Mult Scler. 2023 Oct;29(11-12):1353-1362. doi: 10.1177/13524585231199819. Epub 2023 Sep 23.
Updates in NMOSD and MOGAD Diagnosis and Treatment: A Tale of Two Central Nervous System Autoimmune Inflammatory Disorders.
Cacciaguerra L, Flanagan EP.
Neurol Clin. 2024 Feb;42(1):77-114. doi: 10.1016/j.ncl.2023.06.009. Epub 2023 Aug 7.
Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, Büdingen HV, Klingelschmitt G, Stokmaier D, Bennett JL.
Neurol Neuroimmunol Neuroinflamm. 2022 Dec 8;10(1):e200071. doi: 10.1212/NXI.0000000000200071. Print 2023 Jan.
NMOSD and MOGAD: an evolving disease spectrum.
Uzawa A, Oertel FC, Mori M, Paul F, Kuwabara S.
Nat Rev Neurol. 2024 Oct;20(10):602-619. doi: 10.1038/s41582-024-01014-1. Epub 2024 Sep 13.
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J.
N Engl J Med. 2019 Nov 28;381(22):2114-2124. doi: 10.1056/NEJMoa1901747.
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM.
N Engl J Med. 2019 Aug 15;381(7):614-625. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL; N-MOmentum study investigators.
Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2.
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Kim SH, Gomes ABAGR, Schindler P, Hyun JW, Kim KH, Lee DE, Schoeps VA, Matos AMB, Mendes NT, Apóstolos-Pereira SLD, Callegaro D, Lerner J, Benkert P, Kuhle J, Ruprecht K, Paul F, Pröbstel AK, Kim HJ.
JAMA Neurol. 2025 Feb 1;82(2):168-175. doi: 10.1001/jamaneurol.2024.4400.
Neuromyelitis optica.
Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B.
Nat Rev Dis Primers. 2020 Oct 22;6(1):85. doi: 10.1038/s41572-020-0214-9.
